Adaptive Biotechnologies (NASDAQ:ADPT) CEO Sells $8,058,805.92 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) CEO Chad Robins sold 321,324 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $25.08, for a total transaction of $8,058,805.92. Following the completion of the transaction, the chief executive officer directly owned 2,180,518 shares of the company’s stock, valued at $54,687,391.44. This trade represents a 12.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Adaptive Biotechnologies Stock Up 3.8%

NASDAQ ADPT traded up $0.93 during midday trading on Wednesday, hitting $25.49. 2,145,752 shares of the company traded hands, compared to its average volume of 2,579,911. The company has a debt-to-equity ratio of 2.22, a current ratio of 4.79 and a quick ratio of 4.68. The company has a market cap of $4.07 billion, a PE ratio of -62.17 and a beta of 2.08. The company’s 50-day simple moving average is $21.75 and its 200-day simple moving average is $17.24. Adaptive Biotechnologies Corporation has a 52 week low of $12.00 and a 52 week high of $26.16.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings results on Wednesday, July 29th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.12). Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.The company had revenue of $71.55 million during the quarter, compared to the consensus estimate of $65.44 million. During the same period in the previous year, the firm posted ($0.17) earnings per share. The company’s revenue was up 21.5% on a year-over-year basis. As a group, equities research analysts forecast that Adaptive Biotechnologies Corporation will post -0.4 earnings per share for the current year.

Institutional Trading of Adaptive Biotechnologies

Large investors have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd acquired a new position in Adaptive Biotechnologies during the fourth quarter valued at $28,000. Allworth Financial LP purchased a new position in shares of Adaptive Biotechnologies during the 2nd quarter valued at approximately $35,000. EverSource Wealth Advisors LLC lifted its stake in shares of Adaptive Biotechnologies by 197.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after purchasing an additional 1,565 shares during the period. KBC Group NV acquired a new position in shares of Adaptive Biotechnologies in the 1st quarter valued at $45,000. Finally, Assetmark Inc. boosted its holdings in Adaptive Biotechnologies by 867.9% during the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after buying an additional 2,708 shares in the last quarter. 99.17% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Guggenheim upped their price objective on shares of Adaptive Biotechnologies from $22.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, July 30th. JPMorgan Chase & Co. dropped their target price on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 6th. Morgan Stanley lifted their price objective on shares of Adaptive Biotechnologies from $20.00 to $22.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 30th. Piper Sandler boosted their price objective on shares of Adaptive Biotechnologies from $20.00 to $27.50 and gave the company an “overweight” rating in a report on Tuesday, August 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Friday, July 17th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $24.42.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.